MEDIA
RS Research Announces Online Abstract Acceptance at the 2025 ASCO Annual Meeting
RS Research, a clinically-validated biotechnology company developing targeted oncology therapies with a focus on improved safety and efficacy, announced that an abstract presenting the Phase 1a clinical trial results of its lead candidate, RS_0139, has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL. […]
Prof. Rana Sanyal won the European Prize for Women Innovators
“Women Innovators” Prize in the leading category of the European Prize for Women Innovators program was awarded to RS Research Co-Founder Prof. Rana Sanyal for her successful work in the field of biotechnology. […]
RS Research Announces Poster Presentation at the ESMO TAT 2023 Congress
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as “The Home of Phase I in Oncology”. […]
RS Research Announces Poster Presentation at the ESMO 2022 Congress about RS-0139’s ongoing clinical trial on NSCLC
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology (ESMO) 2022 Congress to be held in person on 9-13 September […]
RS Research Announces Dose Escalation in the Phase I Clinical Study of RS-0139
Designing drug candidates with a superior therapeutic index, RS Research will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC). Medical experts of IDMC recommended […]
RS Research Announces First Patient Dosed in Phase I Clinical Trial of RS-0139 in NSCLC
RS Research announced that the first patient has been dosed in the Phase I clinical trial evaluating the safety of RS-0139 in NSCLC. RS Research’s pipeline is based on the proprietary platform technology Sagitta©, which are nanocarriers with versatile targeting capability and suitable […]
